Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
chemotherapy regimen
|
| gptkbp:activeDuring |
21 days
|
| gptkbp:canBe |
allergic reactions
cardiotoxicity |
| gptkbp:composedOf |
Cyclophosphamide
Docetaxel Doxorubicin |
| gptkbp:developedBy |
clinical research
|
| gptkbp:firstHeld |
early 2000s
|
| https://www.w3.org/2000/01/rdf-schema#label |
TAC regimen
|
| gptkbp:is_monitored_by |
oncologists
|
| gptkbp:isAssociatedWith |
clinical outcomes
improved survival rates quality of life considerations |
| gptkbp:isAttendedBy |
men
women inpatient settings outpatient settings |
| gptkbp:isConsidered |
standard of care
effective |
| gptkbp:isDiscussedIn |
oncology conferences
|
| gptkbp:isDocumentedIn |
medical literature
|
| gptkbp:isEvaluatedBy |
safety
efficacy placebo |
| gptkbp:isInfluencedBy |
genetic factors
tumor characteristics patient health status |
| gptkbp:isInformedBy |
specific dosages
|
| gptkbp:isPartOf |
adjuvant therapy
multimodal treatment approach AC regimen neoadjuvant_therapy TC_regimen |
| gptkbp:isPromotedBy |
patient advocacy groups
|
| gptkbp:isRecognizedFor |
gptkb:NCCN
gptkb:ASCO |
| gptkbp:isReferencedBy |
clinical guidelines
|
| gptkbp:isReviewedBy |
peer-reviewed journals
|
| gptkbp:isStudiedIn |
other cancers
|
| gptkbp:isSubjectTo |
insurance coverage
|
| gptkbp:issuedBy |
intravenous infusion
|
| gptkbp:isUsedIn |
palliative care
combination therapy curative intent |
| gptkbp:isUtilizedIn |
research studies
clinical trials treatment protocols clinical pathways treatment guidelines |
| gptkbp:numberOfEpisodes |
typically 4 to 6
|
| gptkbp:requires |
pre-medication
|
| gptkbp:sideEffect |
fatigue
nausea hair loss low blood cell counts |
| gptkbp:suitableFor |
high-risk breast cancer patients
|
| gptkbp:usedFor |
breast cancer treatment
|